Identification of a novel Raf-1 pathway activator that inhibits gastrointestinal carcinoid cell growth.
about
PI3K-AKT-mTOR-signaling and beyond: the complex network in gastroenteropancreatic neuroendocrine neoplasmsAspirin inhibits cell viability and mTOR downstream signaling in gastroenteropancreatic and bronchopulmonary neuroendocrine tumor cellsInhibition of p70 S6 kinase (S6K1) activity by A77 1726 and its effect on cell proliferation and cell cycle progress.Signaling mechanisms in neuroendocrine tumors as targets for therapy.Overdiagnosis of a typical carcinoid tumor as an adenocarcinoma of the lung: a case report and review of the literature.Chrysin suppresses achaete-scute complex-like 1 and alters the neuroendocrine phenotype of carcinoids.Synergistic effect of pasireotide and teriflunomide in carcinoids in vitro.Teriflunomide, an immunomodulatory drug, exerts anticancer activity in triple negative breast cancer cellsGastroenteropancreatic neuroendocrine tumors: new insights in the diagnosis and therapy.Signaling pathways as specific pharmacologic targets for neuroendocrine tumor therapy: RET, PI3K, MEK, growth factors, and Notch.Achaete-scute complex homologue-1 promotes development of laryngocarcinoma via facilitating the epithelial-mesenchymal transformation.Leflunomide suppresses growth in human medullary thyroid cancer cells.Combined blockade of signalling pathways shows marked anti-tumour potential in phaeochromocytoma cell lines.Hesperetin, a potential therapy for carcinoid cancer.Dihydroorotate dehydrogenase Inhibitors Target c-Myc and Arrest Melanoma, Myeloma and Lymphoma cells at S-phaseCheckpoint kinase 1 inhibition sensitises transformed cells to dihydroorotate dehydrogenase inhibition.Targeted therapy of gastroenteropancreatic neuroendocrine tumours: preclinical strategies and future targets.Measurement of circulating transcripts and gene cluster analysis predicts and defines therapeutic efficacy of peptide receptor radionuclide therapy (PRRT) in neuroendocrine tumors.
P2860
Q26862544-1D1908A9-5C79-44B6-A353-A094AB11D0B8Q34008634-C0877D4F-E022-404D-ABA8-011FE735849AQ34417518-B01F856E-3423-424F-88AF-F65A2CD5342CQ34447484-01009351-AF9B-4E51-9B38-009205571349Q35866294-E3E8D60E-82BB-45B1-BE76-55DCCF43FEA2Q36167254-8FEDDE3E-BE6D-40A4-83F4-0B82E0677FEAQ36536629-698D3F5E-8AAB-4CF6-8FE5-BCDA39E198CAQ37071461-DF93E529-D1ED-4E36-A296-29F598543F5CQ37962416-20714739-E6CC-4032-BC1F-3F61E106F601Q37985518-3573306D-D1CA-47AA-B83A-BB92312EC945Q38700191-58B9F1CE-8694-4557-B751-0F679F282ABDQ39132342-09E542AE-E1F0-4EBA-B781-8557A50DEB18Q39328101-9F4B7854-B47C-4307-A6E9-0CFC927F0AECQ39583082-5D5F07F0-D903-4BE7-8A44-ACCFC1788B67Q41721626-F45B153F-F277-47C8-95E7-11FD6F9D8FECQ47100853-3EBBD3DE-28A5-46D6-A9BA-29B0C41005D5Q47393972-28E2B3B2-FD49-4F8F-AFF8-42BA9D6BBAD6Q50767864-2EB5AFF7-8787-4596-857E-622A8C1E176C
P2860
Identification of a novel Raf-1 pathway activator that inhibits gastrointestinal carcinoid cell growth.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh
2010年學術文章
@zh-hant
name
Identification of a novel Raf- ...... estinal carcinoid cell growth.
@en
Identification of a novel Raf- ...... estinal carcinoid cell growth.
@nl
type
label
Identification of a novel Raf- ...... estinal carcinoid cell growth.
@en
Identification of a novel Raf- ...... estinal carcinoid cell growth.
@nl
prefLabel
Identification of a novel Raf- ...... estinal carcinoid cell growth.
@en
Identification of a novel Raf- ...... estinal carcinoid cell growth.
@nl
P2093
P2860
P1476
Identification of a novel Raf- ...... estinal carcinoid cell growth.
@en
P2093
Herbert Chen
Mackenzie R Cook
Muthusamy Kunnimalaiyaan
Renata Jaskula-Sztul
Scott N Pinchot
P2860
P304
P356
10.1158/1535-7163.MCT-09-0718
P577
2010-01-26T00:00:00Z